文献速递乳腺癌放疗

新型分子亚型预测三阴性乳腺癌局部区域复发

Novel Molecular Subtyping Predicts Locoregional Recurrence in Triple-negative Breast Cancer.
PubMed 文献 · Adv Radiat Oncol · 2025-10-02

该回顾性研究纳入352例接受乳房切除术后放疗的三阴性乳腺癌患者,基于免疫组化分为基底样免疫抑制(BLIS)与非BLIS亚型。

要点

  • 基于免疫组化的BLIS亚型三阴性乳腺癌患者局部区域复发风险更高。
  • BLIS组总生存显著差于非BLIS组,但无病生存无显著差异。
  • 免疫组化分子分型可作为预后标志物指导术后放疗。

核心结论

  • BLIS亚型三阴性乳腺癌患者局部区域复发风险更高,免疫组化分子分型可能作为预后标志物指导乳房切除术后放疗。

关键数值与推荐

  • 基于免疫组化将患者分为基底样免疫抑制(BLIS)和非BLIS组。

临床怎么用

  • 对三阴性乳腺癌患者可依据免疫组化分子分型识别BLIS亚型,该亚型术后放疗后局部区域复发风险较高。
  • 免疫组化分子分型有望作为预后标志物,辅助制定乳房切除术后放疗策略。

局限性

  • 本研究为单中心回顾性分析,样本量352例,中位随访44.6个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immunohistochemistry (IHC)-based molecular subtyping provides a comprehensive profile of triple-negative breast cancer (TNBC). We aimed to elucidate patterns of locoregional recurrence (LRR) in different subtypes of TNBC. METHODS AND MATERIALS: In this study, 352 patients with breast cancer treated with mastectomy and postmastectomy radiation therapy from November 2019 to March 2022 were retrospectively analyzed. Based on IHC, these patients were classified into the basal-like immune-suppressed (BLIS) and non-BLIS groups. We compared LRR as the first event, disease-free survival, and overall survival (OS) between the 2 groups. Univariate and multivariate analysis was performed. RESULTS: The median follow-up time was 44.6 months. Twenty-six LRR (including 9 isolated LRR) and 70 distant metastases (DMs) were observed. The cumulative incidence of LRR was significantly different between the 2 groups, with an LRR rate of 5.8% in the non-BLIS group and 14.9% in the BLIS group (P = .005). The difference in OS was also significant (91.9% vs 83.0%, P = .01). However, there was no significant difference in disease-free survival between the non-BLIS and BLIS groups (80.2% vs 74.5%, P = .35). Multivariate analysis demonstrated that IHC-based molecular subtyping was an independently prognostic factor for LRR and OS (P = .03; P = .03). CONCLUSIONS: This study demonstrated that the BLIS subtype appears to be at a higher risk of developing LRR, and IHC-based molecular subtyping might be used as prognostic biomarkers to guide postmastectomy radiation therapy in patients with TNBC. New strategies that improve locoregional control rates in patients with BLIS are warranted.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Shao S, Shi W, Zhang L, et al. Novel Molecular Subtyping Predicts Locoregional Recurrence in Triple-negative Breast Cancer. Adv Radiat Oncol. 2025. PMID: 41333181. doi:10.1016/j.adro.2025.101909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。